ClinicalTrialsFinder
RecruitingACTRN12611000013965

Inter-ethnic differences in tolerance of anti-cancer drugs in non-small cell lung cancer patients

Exploration of differences in tolerance between Caucasian and Asian non-small cell lung cancer patients receiving palliative chemotherapy with carboplatin and paclitaxel

Sponsor

Sydney Cancer Centre

Enrollment

120 participants

Start Date

Jan 24, 2007

Study Type

Observational

Conditions

tolerance of palliative chemotherapy with carboplatin and paclitaxel in advanced non-small cell lung cancer patients

Summary

Recent evidence shows an ethnic variability in tolerance of anticancer drugs between Asian and Caucasian non-small cell lung cancer patients. Pharmacogenetic differences in drug metabolising enzymes have been proposed as the cause of these differences, however they have not been associated with altered cytotoxic drug pharmacokinetics (PK). Other possible explanations include differences in dietary/concomitant medicine intake and inflammatory status. The aim of this study was to investigate inter-ethnic differences in cytotoxic drug metabolism, inflammatory/nutritional status, genotype and outcomes between Asian and Caucasian non-small cell lung cancer patients.

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Inclusion Criteria7

  • Asian or Caucasian patients.
  • Histologically confirmed advanced non-small cell lung cancer patients
  • receiving chemotherapy with carboplatin AUC 6 and paclitaxel 175 mg/m2
  • Age greater than or equal to 18.
  • Eastern Cooperative Oncology Group (ECOG)Performance Status of 0-2.
  • Ability to comply with the planned procedures and provide written evidence of informed consent.
  • Adequate haematology and biochemistry. (Haemoglobin>100 g/L, White blood cell count >4.0 x 109/L, neutrophil count > 1.5 × 109, platelets >100 x 109/L; Aspartate transaminase (AST), Alanine transaminase (ALT) and bilirubin < 1.5 x ULN (AST, ALT < 5 x upper limit of normal in case liver metastases); calculated creatinine clearance according to Corkroft formula > 60 ml/min.

Exclusion Criteria9

  • Patients who require dose adjustment.
  • Clinical evidence of active brain metastases.
  • Suspected or documented bone marrow involvement.
  • Significant intercurrent illness including active infection, inflammatory bowel disease or other uncontrolled autoimmune disease.
  • The requirement for ongoing systemic treatment with corticosteroids or other immunosuppressive therapy.
  • Patients who have had chemotherapy 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  • Ongoing major side effects from radiology.
  • Other active malignancy.
  • Known allergy to any of the investigational agents.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Observe side effects, nutritional status, inflammatory factors and measure drug clearance of the cycle 1 treatment (21 days): Paclitaxel 175 mg/m2 in 3 hour intravenous infusion, day 0 Carboplatin A

Observe side effects, nutritional status, inflammatory factors and measure drug clearance of the cycle 1 treatment (21 days): Paclitaxel 175 mg/m2 in 3 hour intravenous infusion, day 0 Carboplatin AUC 6 in 1 hour intravenous infusion, day 0 Collect Deoxyribonucleic acid (DNA) samples for pharmacogenomics purpose Toxicity observation is implemented during the first cycle only, response observation is implemented after 3 cycles. Patients recruited over 5 years.

Locations(1)

Shanghai, China

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12611000013965